Core Viewpoint - Hanyu Pharmaceutical is experiencing significant growth, with a projected net profit increase of 1470.82% to 1663.89% for the first half of 2025 compared to the same period last year [1][2] Group 1: Financial Performance - The company expects to achieve a net profit of between 142 million to 162 million yuan for the first half of 2025 [1] - This represents a substantial increase compared to the previous year's performance [1] Group 2: International Business Expansion - Hanyu Pharmaceutical's international business has expanded to core global markets, with APIs sold to over 20 countries and formulations licensed in more than 90 countries [1] - The company is accelerating its internationalization process, which is expected to enhance growth potential [2] Group 3: Innovation in Drug Development - The company focuses on innovative drug development, particularly in the field of peptides and small nucleic acids, with a rich pipeline of future products [2] - The HY3003 project, a GLP-1R/GIPR/GCGR receptor agonist, has completed preclinical candidate screening and is advancing to the pilot scale of API production [1] - The project employs a multi-formulation development strategy, including long-acting monthly injections to improve patient compliance [1] Group 4: Future Product Pipeline - Hanyu Pharmaceutical plans to launch no fewer than 20 formulations globally, including original innovative drugs and micro-innovative drugs [2] - The pipeline includes drugs for treating conditions such as high cholesterol, hypertension, and diabetes, featuring products like Inclisiran and Zilebesiran [2]

Core Viewpoint - The article discusses the initiation of the TRIUMPH-7 Phase III clinical trial by Eli Lilly, which aims to evaluate the efficacy and safety of Retatrutide in patients with obesity or overweight and chronic low back pain, marking the first global Phase III study of GLP1R/GIPR/GCGR triple agonists for pain treatment [2][3]. Group 1 - TRIUMPH-7 is a randomized, double-blind, placebo-controlled international multicenter study expected to start in June 2025 and complete by September 2027 [3]. - The trial plans to enroll 586 participants who will be randomly assigned to receive either weekly injections of Retatrutide or a placebo for 80 weeks [3]. - Primary endpoints include the change in pain intensity from baseline and the percentage change in weight from baseline, while secondary endpoints cover the number of patients achieving pain relief and weight loss targets [3]. Group 2 - Retatrutide is classified as a GLP1R/GIPR/GCGR triple agonist and is currently the fastest advancing candidate in this field, undergoing Phase III trials for multiple indications including obesity, type 2 diabetes, secondary prevention of cardiovascular events, and obstructive sleep apnea [3].

Core Viewpoint - The collaboration between Hanyu Pharmaceutical and Shenzhen Carbon Cloud Smart Peptide Technology Co., Ltd. aims to develop a novel peptide drug targeting GLP-1R/GIPR/GCGR for metabolic disease treatment, particularly for weight control [2][3]. Group 1: Collaboration Details - Hanyu Pharmaceutical will handle preclinical research, IND application, clinical trials, and product registration, covering associated costs [3]. - Carbon Cloud Smart Peptide will be responsible for molecular screening and will bear all development costs during this process [3]. - Hanyu Pharmaceutical will pay up to 38 million yuan in milestone payments to Carbon Cloud Smart Peptide and will share revenue based on sales, with a maximum of 10% for North America and 3% for other global regions [3]. Group 2: Market Position and Product Development - Hanyu Pharmaceutical has established a strong position in the GLP-1 market, particularly with its experience in the development of liraglutide and other peptide products [4]. - The collaboration marks Hanyu Pharmaceutical's entry into the innovative research frontier of weight loss drugs, enhancing its global standing in the GLP-1 sector [4]. - The new drug is expected to show significant weight loss effects in preclinical studies, outperforming existing treatments like terzepatide in specific metrics [5][6].